Company Filing History:

11 out of 8,282

Nokia Corporation

Years Active: 2009-2022

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11352346 - Process for the preparation of 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole and the hydrogensulfate salt thereof (2022-06-07),

2. 11098032 - Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors (2021-08-24),

3. 10717726 - Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors (2020-07-21),

4. 9249127 - Alpha2 adrenoceptor agonists (2016-02-02),

5. 8832595 - Mobile communications terminal and method (2014-09-09),

6. 8799802 - Apparatus, method and computer program product enabling zoom function with multi-function key input that inhibits focus on a textually-responsive element (2014-08-05),

7. 8745515 - Presentation of large pages on small displays (2014-06-03),

8. 8472329 - Presenting confirmation queries for network usage (2013-06-25),

9. 8365093 - Apparatus, method and computer program product enabling storage of state of temporary display screen magnification view (2013-01-29),

10. 8302029 - Presentation of large objects on small displays (2012-10-30),

11. 7594194 - Portrayal of navigation objects (2009-09-22),

12. 7581174 - Displaying a web page in a browser window and a method for handling a web page (2009-08-25),

13. 7565604 - Method and a system for displaying information, and a device (2009-07-21),

14. 7516402 - Presentation of large objects on small displays (2009-04-07),

15. 7509575 - Optimization of content (2009-03-24),

Title: Mikko Kalervo Mäkelä: Innovator in Pharmaceutical Processes

Introduction

Mikko Kalervo Mäkelä is a prominent inventor based in Tampere, Finland. With an impressive portfolio of 15 patents, he has made significant contributions in the field of pharmaceuticals, particularly in the development of innovative compounds for medical applications.

Latest Patents

Among his latest works, Mäkelä has developed a method for preparing 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole and its hydrogensulfate salt. This advanced process enhances the production of an isochroman-structured alpha2A adrenoceptor agonist, which holds therapeutic potential for treating anxiety and serves as a sedative or analgesic agent. His research has also yielded pyran derivatives functioning as CYP11A1 inhibitors, showcasing his dedication to addressing important health challenges.

Career Highlights

Mäkelä's career took shape with respected institutions such as Nokia Corporation and Orion Corporation, where he gained valuable experience and honed his expertise in the pharmaceutical sector. His efforts in these organizations have solidified his reputation as an authoritative figure in the innovation of therapeutic compounds.

Collaborations

Throughout his career, Mäkelä has collaborated with noteworthy peers including David Din Belle and Mikko Passiniemi. These partnerships have facilitated the exchange of ideas and knowledge, further enhancing the impact of his inventions in the pharmaceutical field.

Conclusion

Mikko Kalervo Mäkelä continues to be a significant force in innovation, contributing to advancements in pharmaceutical processes and treatments. With his impressive patent portfolio and collaborative spirit, he is poised to make even more impactful contributions to the healthcare industry in the future.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.